Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 38 Earnings per Share (Diluted) is €1.83 as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €11.44. The stock has 4 warning signs investors should review. Among 1,168 Biotechnology companies, VivoSim Labs ranks better than 58.65% on this metric.
VivoSim Labs's EPS (Basic) for the
three
months ended in Dec. 2025 was €-0.88.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83.
VivoSim Labs's EPS without NRI for the
three
months ended in Dec. 2025 was €-0.88.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 22.20% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 22.10% per year.
During the past 13 years, VivoSim Labs's highest 3-Year average EPS without NRI Growth Rate was 34.00% per year. The lowest was -533.40% per year. And the median was 13.00% per year.
VivoSim Labs (FRA:4OR) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
VivoSim Labs Earnings per Share (Diluted) Related Terms
VivoSim Labs Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, VivoSim Labs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's PE Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's PE Ratio falls into.
VivoSim Labs Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
VivoSim Labs's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €1.83 mean?
VivoSim Labs (FRA:4OR) has a Earnings per Share (Diluted) of €1.83 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #483 out of 1168 companies in the Biotechnology industry, placing it in the top 41.4%.
Is VivoSim Labs' Earnings per Share (Diluted) too high?
VivoSim Labs' current Earnings per Share (Diluted) is €1.83. Based on the distribution chart, VivoSim Labs ranks #483 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Earnings per Share (Diluted) compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #483 out of 1168 companies for Earnings per Share (Diluted). This puts VivoSim Labs in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Earnings per Share (Diluted) is €1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Earnings per Share (Diluted) of €1.83. The stock's GF Value™ is €11.44, compared to a current price of €3.49 — trading 69.5% below its estimated fair value. The current Earnings per Share (Diluted) is €1.83. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Earnings per Share (Diluted) is €1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 69.5% below its estimated GF Value™ of €11.44.
Key valuation signals for FRA:4OR:
Earnings per Share (Diluted): €1.83
GF Value™: €11.44 vs. price of €3.49 (69.5% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
